Schroder Investment Management Group
ASND icon

Schroder Investment Management Group’s Ascendis Pharma A/S ASND Stock Holding History

Schroder Investment Management Group’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-67,902
Closed -$14.8M – 1177
2026
Q1 		$14.8M Sell
67,902
-5,408
-7% -$1.21M 0.01% 584
2025
Q4 		$15.6M Buy
73,310
+39,919
+120% +$8.24M 0.01% 564
2025
Q3 		$6.64M Sell
33,391
-23,598
-41% -$4.4M 0.01% 731
2025
Q2 		$9.84M Sell
56,989
-47,928
-46% -$7.81M 0.01% 641
2025
Q1 		$16.2M Buy
104,917
+12,189
+13% +$1.74M 0.02% 555
2024
Q4 		$12.7M Buy
92,728
+11,739
+14% +$1.54M 0.01% 603
2024
Q3 		$11.7M Buy
80,989
+36,071
+80% +$4.87M 0.01% 633
2024
Q2 		$6.13M Buy
+44,918
New +$6.11M 0.01% 736
2023
Q2 		– Sell
-60,221
Closed -$6.46M – 1229
2023
Q1 		$6.46M Hold
60,221
– – 0.01% 732
2022
Q4 		$7.35M Buy
60,221
+2,094
+4% +$243K 0.01% 700
2022
Q3 		$6M Buy
58,127
+6,953
+14% +$659K 0.01% 732
2022
Q2 		$4.76M Buy
51,174
+869
+2% +$81.9K 0.01% 798
2022
Q1 		$5.84M Buy
50,305
+13,362
+36% +$1.55M 0.01% 802
2021
Q4 		$4.97M Buy
36,943
+1,695
+5% +$252K 0.01% 760
2021
Q3 		$5.62M Buy
35,248
+12,468
+55% +$1.71M 0.01% 763
2021
Q2 		$3M Buy
22,780
+1,723
+8% +$230K ﹤0.01% 938
2021
Q1 		$2.71M Buy
21,057
+2,110
+11% +$321K ﹤0.01% 954
2020
Q4 		$3.16M Sell
18,947
-441
-2% -$72.9K ﹤0.01% 909
2020
Q3 		$3.08M Buy
19,388
+1,659
+9% +$238K ﹤0.01% 820
2020
Q2 		$2.62M Buy
17,729
+3,191
+22% +$438K ﹤0.01% 781
2020
Q1 		$1.72M Buy
14,538
+46
+0.3% +$5.98K ﹤0.01% 820
2019
Q4 		$2.02M Hold
14,492
– – ﹤0.01% 877
2019
Q3 		$1.39M Buy
+14,492
New +$1.62M ﹤0.01% 939

Other funds holding ASND

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Schroder Investment Management Group's ASND Position: Q2 2026 in Review

Schroder Investment Management Group sold out of Ascendis Pharma A/S (ASND) in Q2 2026, closing a stake of 67,902 shares — an estimated $14.8M sold.

Schroder Investment Management Group first reported a position in ASND in Q3 2019 and held it in 23 quarters. The position peaked at $16.2M in Q1 2025. 313 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

  • Schroder Investment Management Group reported no remaining Ascendis Pharma A/S position as of Q2 2026 after selling out during the quarter.
  • Schroder Investment Management Group sold 67,902 Ascendis Pharma A/S shares in Q2 2026, an estimated $14.8M.
  • Schroder Investment Management Group first reported a position in Ascendis Pharma A/S in Q3 2019 and held it in 23 quarters.
  • Schroder Investment Management Group's Ascendis Pharma A/S position peaked at $16.2M in Q1 2025.
  • 313 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Schroder Investment Management Group's 13F filing for Q2 2026, filed 13 Aug 2026.